ClinicalTrials.gg

Program

Aprepitant

Also written as “aprepitant”, “MK0869, aprepitant” and “Aprepitant Injection”.

Its studies are mostly in Depressive Disorder, Major · Vomiting · Nausea · Postoperative Nausea and Vomiting · Pruritus, led by 7 companies.

Furthest: phase 4, since Sep 21, 200427 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck210 open or runningphase 4since Sep 21, 2004May 2, 2002none ahead
CSPC Pharmaceutical Group11 open or runningphase 3since Jul 17, 2024Jul 17, 2024none ahead
Lahore Medical Research Center, LLP10 open or runningphase 3since Feb 23, 2024Feb 23, 2024none ahead
LEO Pharma10 open or runningphase 2since Sep 18, 2013Sep 18, 2013none ahead
Nuformix Technologies10 open or runningphase 1since Mar 20, 2019Mar 20, 2019none ahead
Ono Pharmaceutical10 open or runningphase 2since Sep 13, 2005Sep 13, 2005none ahead
Qilu Pharmaceutical10 open or runningphase 3since Apr 10, 2025Apr 10, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since May 2, 2002.

  1. Sep 13, 2005Ono Pharmaceutical's first study: phase 2 study in NeoplasmsNew to Ono PharmaceuticalOno Pharmaceutical · NCT00212602 · 420 enrolled · Japan
  2. Jun 14, 2006Phase 3 study in VomitingMerck · NCT00337727 · 848 enrolled
  3. Jan 6, 20092 phase 1 studiesMerck · NCT00818259, NCT00819039
  4. Jul 23, 2009Phase 1 study in VomitingMerck · NCT00945321 · 42 enrolled
  5. Jul 31, 2009Phase 3 study in VomitingMerck · NCT00952341 · 421 enrolled
  6. Oct 6, 2009Phase 1 study in VomitingMerck · NCT00990821 · 188 enrolled
  7. May 26, 2011Phase 3 study in VomitingMerck · NCT01362530 · 307 enrolled
  8. Jul 5, 2012Phase 4 study in NauseaMerck · NCT01636947 · 494 enrolled
  9. Nov 19, 2012Phase 2 study in Post-operative NauseaMerck · NCT01732458 · 229 enrolled
  10. Sep 18, 2013LEO Pharma's first study: phase 2 study in PruritusNew to LEO PharmaLEO Pharma · NCT01963793 · 20 enrolled · Germany
  11. Mar 20, 2019Nuformix Technologies's first study: phase 1 study in HealthyNew to Nuformix TechnologiesNuformix Technologies · NCT03889366 · 12 enrolled · United Kingdom
  12. Feb 23, 2024Lahore Medical Research Center, LLP's first study: phase 3 study in Primary DysmenorrheaNew to Lahore Medical Research Center, LLPLahore Medical Research Center, LLP · NCT06317064 · 40 enrolled · Pakistan
  13. Jul 17, 2024CSPC Pharmaceutical Group's first study: phase 3 study in VomitingNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06543966 · 486 planned
  14. Apr 10, 2025Qilu Pharmaceutical's first study: phase 3 study in Postoperative Nausea and VomitingNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT06932107 · 518 enrolled · China

TargetBeta

TACR1 →read by rule
“Neurokinin 1 receptor antagonist”ChEMBL 37, by rule

Other programs on TACR1

ProgramCompanyFurthest phaseStudies
elinzanetantruleBayerphase 324
tradipitantruleVanda Pharmaceuticalsphase 319
fosnetupitantruleHelsinn Healthcarephase 32
HRS5580Jiangsu HengRui Medicinephase 22

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06932107Postoperative Nausea and Vomiting · China3CompletedQilu PharmaceuticalMay 28, 2024518
NCT06543966Vomiting3Not yet recruitingCSPC Pharmaceutical GroupMar 28, 2026486
NCT06317064Primary Dysmenorrhea · Pakistan3CompletedLahore Medical Research Center, LLPOct 31, 202440
NCT03889366Healthy · United Kingdom1CompletedNuformix TechnologiesApr 15, 201912
NCT01963793Pruritus · Germany2CompletedLEO PharmaJul 201420
NCT01732458Post-operative Nausea2CompletedMerckSep 26, 2016229
NCT01636947Nausea4CompletedMerckAug 4, 2014494
NCT01362530Vomiting3CompletedMerckMar 14, 2013307
NCT00990821Vomiting1CompletedMerckDec 2005188
NCT00952341Vomiting3CompletedMerckApr 4, 2010421
NCT00945321Vomiting1CompletedMerckMar 200942
NCT00819039Postoperative Nausea and Vomiting · United States, Brazil, Mexico and more1CompletedMerckMar 12, 201398
NCT00818259Vomiting1TerminatedMerckJan 20, 201492
NCT00337727Vomiting3CompletedMerckOct 28, 2008848
NCT00212602Neoplasms · Japan2CompletedOno Pharmaceutical420
NCT00092196Nausea3CompletedMerckDec 1, 2004820
NCT00092183Nausea4CompletedMerckDec 1, 2003866
NCT00080444Vomiting3CompletedMerckSep 200650
NCT00048607Depressive Disorder, Major3CompletedMerckDec 31, 2003600
NCT00048594Depressive Disorder, Major3CompletedMerckDec 18, 2003800
NCT00042029Depressive Disorder, Major3CompletedMerckOct 3, 2003324
NCT00035295Depressive Disorder, Major3CompletedMerckDec 5, 2003584
NCT00035282Depressive Disorder, Major3CompletedMerckDec 2003450
NCT00035048Depressive Disorder, Major3CompletedMerckDec 29, 2003540
NCT00035009Depressive Disorder, Major3CompletedMerckDec 22, 2003468
NCT00034983Depressive Disorder, Major3CompletedMerckDec 29, 2003900
NCT00034944Depressive Disorder, Major3CompletedMerckDec 17, 2003495

How it is read

Names in the registry

  • “aprepitant”, 8 entries
  • “Aprepitant”, 4 entries
  • “MK0869, aprepitant”, 4 entries
  • “Aprepitant Injection”, 2 entries
  • “Aprepitant 125 mg”, 2 entries

Codes read as this program: MK0869.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.